Advertisement

Investigational New Drugs

, Volume 25, Issue 1, pp 69–75 | Cite as

Phase II trial of interferon and thalidomide in metastatic renal cell carcinoma

  • Ulka N. VaishampayanEmail author
  • Lance K. Heilbrun
  • Anthony F. Shields
  • Jawana Lawhorn-Crews
  • Karen Baranowski
  • Daryn Smith
  • Lawrence E. Flaherty
Phase II Studies

Summary

Objectives: To evaluate the toxicity and efficacy of interferon and thalidomide combination in a phase II clinical trial.

Patients and methods: Eligibility included metastatic renal cancer with a maximum of two prior regimens, performance status of 0‐2 and adequate renal, hepatic and bone marrow function.

Results: Twenty patients were enrolled on this phase II trial. Median age was 60.5 years (Range: 39–75 years). 17 patients had visceral metastases (lung/liver/both) and 3 patients had lymph node only metastases. A total of 26 cycles of 4 weeks each were administered; median of 1 cycle and range from 0‐9 cycles. The therapy was poorly tolerated with grade 3 adverse events noted in 12 (60%) of the 20 patients. No objective responses were noted. Of the 14 response evaluable patients, one had an unconfirmed response (38% decrease in size) and one had prolonged disease stabilization for 10 months. The median time to progression was 1.0 month and median survival was 2.8 months. Pre and post therapy PET scans were performed nine weeks apart on one patient. The mean standardized uptake values (SUV) declined from 1.45 (SUV min-max 0.89–1.76) to 1.12 (SUV min-max 0.55–1.47), denoting anti vascular effect. The patient did not have an objective response but had a disease stabilization sustained for 10 months.

Conclusion: The combination of interferon and thalidomide has minimal efficacy and considerable toxicity which makes this combination unworthy of future investigation in metastatic renal cancer.

Keywords

Renal cancer Immunotherapy Phase II clinical trial Interferon Thalidomide 

Notes

Acknowledgments

Supported in part by a grant from the Dept. of Internal Medicine, Wayne State University, Detroit MI, by Schering Inc., Celgene Corp, and by NIH Cancer Center Support Grant CA-22453

References

  1. 1.
    Sokoloff MH, Figlin RA, de Kernion JB, Belldegrun AS (1997) Systemic immunotherapy for genitourinary neoplasms. In: Raghavan D, Scher HI, Leibel SA, Lange P (eds) Principles and practice of genitourinary oncology, Lippincott-Raven, Philadelphia, pp 869–883Google Scholar
  2. 2.
    Motzer RJ, Vogelzang NJ (1997) Chemotherapy for renal cell carcinoma. In: Raghavan D, Scher HI, Leibel SA, Lange P (eds) Principles and practice of genitourinary oncology, Lippincott-Raven, Philadelphia, pp 885–896Google Scholar
  3. 3.
    Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, Steinberg SM, Chen HX, Rosenberg SA (2003) A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349:427–434PubMedCrossRefGoogle Scholar
  4. 4.
    Escudier B, Szczylik C, Eisen T, Stadler WM, Schwartz B, Shan M, Bukowski RM (2005) Randomized Phase III trial of the raf kinase and VEGFR inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC). Proc ASCO (abstract #4510)Google Scholar
  5. 5.
    Motzer RJ, Rini BI, Michaelson MD, Redman BG, Hudes GR, Wilding G, Bukowski RM, George DJ, Kim ST, Baum CM, The SU11248 Study Group (2005) Phase 2 trials of SU11248 show antitumor activity in second-line therapy for patients with metastatic renal cell carcinoma (RCC). Proc ASCO (abstract #4508)Google Scholar
  6. 6.
    Nanus DM, Pfeffer LM, Bander NH, Bahri S, Albino AP (1990) Antiproliferative and antitumor effects of alpha interferon in renal cell carcinomas: correlation with the expression of a kidney associated differentiation glycoprotein. Cancer Res 50:4190–4194PubMedGoogle Scholar
  7. 7.
    Sidky YA, Borden EC (1987) Inhibition of angiogenesis by interferons: effects on tumor and lymphocyte induced vascular responses. Cancer 47:5155–5161Google Scholar
  8. 8.
    Brem H, Gresser I, Grosfeld J, Folkman J (1993) The combination of antiangiogenic agents to inhibit primary tumor growth and metastasis. J Pediatr Surg 8:1253–1257CrossRefGoogle Scholar
  9. 9.
    Minasian LM, Motzer RJ, Gluck L, Mazumdar M, Vlamis V, Krown SE (1993) Interferon alfa-2a in advanced renal cell carcinoma: treatment results and survival in 159 patients with long term follow-up. J Clin Oncol 11:1368–1375PubMedGoogle Scholar
  10. 10.
    Motzer RJ, Bander NH, Nanus DM (1996) Renal cell carcinoma. N Engl J Med 335:865–875PubMedCrossRefGoogle Scholar
  11. 11.
    Gleave ME, Elhilali M, Fradet Y, Davis I, Venner P, Saad F, Klotz LH, Moore MJ, Paton V, Bajamonde A (1998) Interferon gamma 1b compared with placebo in metastatic renal cell carcinoma. N Engl J Med 338:1265–1271PubMedCrossRefGoogle Scholar
  12. 12.
    Negrier S, Escudier B, Lasset C, Douillard JY, Savary J, Chevreau C, Ravaud A, Mercatello A, Peny J, Mousseau M, Philip T, Tursz T (1998) Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal cell carcinoma. N Engl J Med 338:1272–1278PubMedCrossRefGoogle Scholar
  13. 13.
    Knight R (2005) IMiDs: a novel class of immunomodulators. Semin Oncol 32(4 Suppl 5):S24–S30PubMedCrossRefGoogle Scholar
  14. 14.
    Moreira AL, Sampaio EP, Zmuidzinas A, Frindt P, Smith KA, Kaplan G (1993) Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. J Exp Med 177:1675–1680PubMedCrossRefGoogle Scholar
  15. 15.
    Ching LM, Xu ZF, Gummer BH, Palmer BD, Joseph WR, Baguley BC (1995) Effect of thalidomide on tumour necrosis factor production and anti-tumour activity induced by 5,6-dimethylxanthenone-4-acetic acid. British J Cancer 72:339–343Google Scholar
  16. 16.
    D'Amato RJ, Loughnan MS, Flynn E, Folkman J (1994) Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci 91:4082–4085PubMedCrossRefGoogle Scholar
  17. 17.
    Kruse FE, Jousee AM, Rohrschneider K, Becker MD, Volcker HE (1998) Thalidomide inhibits corneal angiogenesis induced by vascular endothelial growth factor. Graefe's Arch Clin Exp Ophthal 236:461–466CrossRefGoogle Scholar
  18. 18.
    Amato RJ (2002) Thalidomide: an antineoplastic agent. Curr Oncol Rep Jan 4:56–62Google Scholar
  19. 19.
    Shields AF (2003) PET imaging with 18F-FLT and thymidine analogs: promise and pitfalls. J Nucl Med 44:1432–1434PubMedGoogle Scholar
  20. 20.
    Simon R (1989) Optimal two-stage designs for phase II clinical trials. Contr Clini Trials 10:1–10PubMedCrossRefGoogle Scholar
  21. 21.
    Casella G (1987) Refining binomial confidence intervals. Canadian J Statistics 14:113–129Google Scholar
  22. 22.
    Mehta C, Patel N (1999) StatXact 5: statistical software for exact nonparametric inference, user manual. Cytel Software CorporationGoogle Scholar
  23. 23.
    Lee E (1992) Statistical methods for survival data analysis, 2nd edn. Wiley & Sons, IncGoogle Scholar
  24. 24.
    Daliani DD, Papandreou CN, Thall PF, Wang X, Perez C, Oliva R, Pagliaro L, Amato R (2002) A pilot study of thalidomide in patients with progressive metastatic renal cell carcinoma. Cancer 95:758–765PubMedCrossRefGoogle Scholar
  25. 25.
    Escudier B, Lassau N, Couanet D, Angevin E, Mesrati F, Leborgne S, Garofano A, Leboulaire C, Dupouy N, Laplanche A (2002) Phase II trial of thalidomide in renal-cell carcinoma. Ann Oncol 13:1029–1035PubMedCrossRefGoogle Scholar
  26. 26.
    Clark PE, Hall MC, Miller A, Ridenhour KP, Stindt D, Lovato JF, Patton SE, Brinkley W, Das S, Torti FM (2004) Phase II trial of combination interferon-alpha and thalidomide as first-line therapy in metastatic renal cell carcinoma. Urology 63:1061–1065PubMedCrossRefGoogle Scholar
  27. 27.
    Hernberg M, Virkkunen P, Bono P, Ahtinen H, Maenpaa H, Joensuu H (2003) Interferon alfa-2b three times daily and thalidomide in the treatment of metastatic renal cell carcinoma. J Clin Oncol 21:3770–3776PubMedCrossRefGoogle Scholar
  28. 28.
    Gordon MS, Manola J, Fairclough D, Cella D, Richardson R, Sosman J, Kasimis B, Dutcher JP, Wilding G (2004) Low dose interferon-α2b (IFN) + thalidomide (T) in patients (pts) with previously untreated renal cell cancer (RCC). Improvement in progression-free survival (PFS) but not quality of life (QoL) or overall survival (OS). A phase III study of the Eastern Cooperative Oncology Group (E2898). Proc ASCO (abstract #4516)Google Scholar
  29. 29.
    Motzer RJ, Bacik J, Schwartz LH, Reuter V, Russo P, Marion S, Mazumdar M (2004) Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol 22:454–463PubMedCrossRefGoogle Scholar
  30. 30.
    Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, O'Toole T, Park Y, Moore L (2006) A phase 3, randomized, 3-arm study of temsirolimus (TEMSR) or interferon-alpha (IFN) or the combination of TEMSR + IFN in the treatment of first-line, poor-risk patients with advanced renal cell carcinoma (adv RCC). Proc ASCOLB (abstract #4)Google Scholar
  31. 31.
    Nathan PD, Gore ME, Eisen TG (2002) Unexpected toxicity of combination thalidomide and interferon alpha-2a treatment in metastatic renal cell carcinoma. J Clin Oncol 20:1429–1430PubMedGoogle Scholar
  32. 32.
    Ratain MJ, Eisen T, Stadler WM, Flaherty KT, Kaye SB, Rosner GL, Gore M, Desai AA, Patnaik A, Xiong HQ, Rowinsky E, Abbruzzese JL, Xia C, Simantov R, Schwartz B, O'Dwyer PJ (2006) Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 24:2505–2512PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science + Business Media, LLC 2006

Authors and Affiliations

  • Ulka N. Vaishampayan
    • 1
    • 3
    Email author
  • Lance K. Heilbrun
    • 2
  • Anthony F. Shields
    • 1
  • Jawana Lawhorn-Crews
    • 1
  • Karen Baranowski
    • 1
  • Daryn Smith
    • 2
  • Lawrence E. Flaherty
    • 1
  1. 1.Division of Oncology, Department of Medicine, Barbara Ann Karmanos Cancer InstituteWayne State UniversityDetroitUSA
  2. 2.Biostatistics UnitBarbara Ann Karmanos Cancer InstituteDetroitUSA
  3. 3.4 Hudson Webber Cancer Research CenterDetroitUSA

Personalised recommendations